Using superagonist, CD28-specific monoclonal antibodies, or their mimics, for treatment and prevention of autoimmune inflammation and for immune system reconstitution

Use of CD28-specific, superagonistic monoclonal antibodies (mAb), or their mimic compounds, to prepare a composition (a) for treatment and prevention of autoimmune-mediated inflammatory disease or (b) for immune system reconstitution. The dose of mAb is below of first threshold in (a) but above a second threshold in (b). ACTIVITY : Antiinflammatory; Antirheumatic; Antiarthritic; Neuroprotective; Antidiabetic; Antipsoriatic; Immunosuppressive; Cytostatic; Anti-HIV; Virucide; Immunostimulant. The anti-CD28 superagonistic antibody JJ316 was tested in the adjuvant arthritis model of J. Clin. Invest., 101 (1998) 2910. Test rats were injected on days 0 and 10 with 0.2 or 1 mg JJ316, and with heat-killed Mycobacterium tuberculosisand incomplete Freund's adjuvant day 0. In untreated controls, the arthritis index reached a peak on about day 18 of 9-10; for animals given 0.2 mg doses of JJ316 the maximum score was about 2, on day 18, and for those given 1 mg JJ316 it was about 3, on day 16. Other results are given showing activity against established arthritis. MECHANISM OF ACTION : CD28 agonist. Die Erfindung betrifft die Verwendung eines CD28-spezifischen superagonistischen monoklonalen Antikörpers (mAb) oder einer Mimikriverbindung hierzu, zur Herstellung einer pharmazeutischen Zusammensetzung, wobei die Dosis unterhalb oder oberhalb einer definierten Grenzdosis liegt.